Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TYMP | P19971 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484547 | 0.78 | ALDH1A1 (0.34) | HRH3DAOALDH1A1TYMP | |
| SCHEMBL9409027 | 0.76 | ACHE (0.33) | HRH3DAOALDH1A1 | |
| Hydrochloric Acid SCHEMBL9266364 | 0.74 | ACHE (0.32) | HRH3ALDH1A1 | |
| SCHEMBL535752 | 0.73 | ACHE (0.39) | ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL535435 | 0.72 | ACHE (0.39) | ALDH1A1LMNA | |
| SCHEMBL9263485 | 0.72 | ACHE (0.39) | ALDH1A1LMNA | |
| SCHEMBL8958282 | 0.70 | BACE1 (0.33) | SMN1; SMN2 | |
| SCHEMBL8958290 | 0.70 | BACE1 (0.33) | SMN1; SMN2 | |
| SCHEMBL8958172 | 0.69 | BACE1 (0.50) | LMNA | |
| SCHEMBL8958239 | 0.67 | BACE1 (0.34) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| EP-2049107-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | Genfit (FR) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012470-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | GENFIT (FR) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012470-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | GENFIT (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | IPO5, PPIP5K2, IPO4 | HRH3 387/4885DAO 1855/4885ALDH1A1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.